Dramatic Survival Gain Feasible in ALK+ NSCLC
MedPage Today,
Long-term survival in stage IV ALK-positive non-small cell lung cancer (NSCLC) improved dramatically following the introduction…
Long-term survival in stage IV ALK-positive non-small cell lung cancer (NSCLC) improved dramatically following the introduction…
Action Points Note that this study of an antibody-conjugated irinotecan metabolite for heavily pre-treated lung cancer showed…
In his final State of the Union address one year ago, President Obama announced a “moonshot” initiative to “cure cancer once…
CET Approval is the First for Necitumumab in Europe INDIANAPOLIS, Feb. 16, 2016 /PRNewswire/ -- Eli Lilly and Company today…
INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S.